CTLA4 and neoplasm: Mice immunised with (MS@OVAinMOF)@(anti-CTLA4inMOF) show a higher ratio of tumour-free mice, significantly higher survival rate, and significantly smaller tumour volume than those administrated with (OVAinMOF)@(anit-CTLA4inMOF), free OVA-anti-CTLA4, and only saline.